- Home
- SOHU vs INBX Comparison
SOHU vs INBX Comparison
Compare SOHU & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOHU | INBX |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.4M | 430.2M |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SOHU | INBX |
|---|---|---|
| Price | $15.68 | $89.43 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 40.2K | ★ 261.6K |
| Earning Date | 11-17-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 5.11 | N/A |
| Revenue | ★ $576,757,000.00 | $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | $2.29 | $230.77 |
| P/E Ratio | $3.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.79 | $10.81 |
| 52 Week High | $16.45 | $90.58 |
Technical Indicators
Market Signals| Indicator | SOHU | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 70.37 |
| Support Level | $14.94 | $78.82 |
| Resistance Level | $15.90 | $86.23 |
| Average True Range (ATR) | 0.68 | 5.66 |
| MACD | 0.09 | -0.72 |
| Stochastic Oscillator | 80.60 | 97.05 |
Price Performance
Historical ComparisonAbout SOHU Sohu.com Limited
Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.